New research reveals previously unknown ways opioid receptors can function, opening the door to safer pain treatments.
As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...
2UrbanGirls on MSN
Gonadorelin: A peptide gateway into endocrine and reproductive research
Peptides have long attracted attention in the scientific community due to their structural simplicity yet vast range of ...
An internationally recognized leader in molecular pharmacology and neurobiology, Dr. Bohn recently joined USF Health. She is ...
Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.
Vasoactive Intestinal Peptide (VIP) has remained a molecule of considerable scientific interest since its initial characterization as a 28–amino acid neuropeptide with widespread distribution ...
Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.
Up-to-date computational pipeline characterizes G-protein-coupled receptor (GPCR) repertoires in the closest relatives of metazoans, providing a framework to investigate the evolutionary origins and ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback